Imatinib
Childhood Desmoplastic Small Round Cell Tumor
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Childhood Desmoplastic Small Round Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | B |
Fludarabine St. Jude Children's Research Hospital | Phase 2 | B |
TACROLIMUS M.D. Anderson Cancer Center | Phase 2 | CCC |
ETOPOSIDE M.D. Anderson Cancer Center | Phase 2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II Mayo Clinic | Phase 1 | CCC |
View all 30 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →